Internal Medicine, Endocrinology, Diabetes, & Metabolism · Mountain View, CA
NPI
1033362041
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2204 Grant Rd, Suite 103
Mountain View, CA, 94040
Phone (650) 967-8841
Groups this clinician bills Medicare through
Medicare paid, 2024
$129K
4,006 services
Medicare patients, 2024
189
Average age 75
Drug cost, 2024
$480K
1,232 prescriptions
Company payments, 2025
$1,729
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Preethi C Sridhar was code J0897 (injection, denosumab, 1 mg), 3,120 times for 31 patients. In total Preethi C Sridhar billed 4,006 services in 14 codes, and Medicare paid $129K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-02-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,120 | 31 | $20.31 | $63K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 226 | 120 | $14.53 | $3,284 |
| 99214 Office E&M - Established | Office | 215 | 119 | $111.16 | $24K |
| 99213 Office E&M - Established | Office | 134 | 81 | $76.15 | $10K |
| 99215 Office E&M - Established | Office | 111 | 71 | $152.89 | $17K |
| 95251 Test - Miscellaneous | Office | 74 | 28 | $29.14 | $2,156 |
| 96372 Injection Administration | Office | 55 | 32 | $13.99 | $769 |
| 76536 Ultrasound - Nonspecific | Office | 41 | 39 | $112.19 | $4,600 |
| 99204 Office E&M - New | Office | 12 | 12 | $150.29 | $1,803 |
By year: 2022 $98K for 3,403 services; 2023 $102K for 3,595 services; 2024 $129K for 4,006 services.
Medicare prescription drug claims, 2024
In 2024, the drug Preethi C Sridhar prescribed most often to Medicare patients was Levothyroxine Sodium, with 130 prescriptions and refills. In total Preethi C Sridhar wrote 1,232 Medicare prescriptions that cost $480K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 130 | 386 | 44 | $1,930 |
| Metformin Hcl Generic | 73 | 219 | 20 | $942 |
| Metformin Hcl Er Metformin Hcl | 60 | 178 | 24 | $749 |
| Synthroid Levothyroxine Sodium | 57 | 171 | 15 | $4,719 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 57 | 142 | 19 | $6,475 |
| Amlodipine Besylate Generic | 48 | 138 | 15 | $333 |
| Losartan Potassium Generic | 44 | 132 | 13 | $298 |
| Rosuvastatin Calcium Generic | 41 | 123 | 12 | $940 |
| Ramipril Generic | 38 | 96 | Under 11 | $434 |
| Ozempic Semaglutide | 36 | 70 | Under 11 | $65K |
| Jardiance Empagliflozin | 34 | 90 | 15 | $53K |
| Pravastatin Sodium Generic | 27 | 81 | Under 11 | $242 |
| Atorvastatin Calcium Generic | 26 | 78 | Under 11 | $293 |
| Tresiba Flextouch U-100 Insulin Degludec | 25 | 69 | 11 | $16K |
| Simvastatin Generic | 23 | 69 | Under 11 | $221 |
Brand drugs: 398 claims; generic drugs: 718 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Preethi C Sridhar $1,729 ($1,729 in general payments such as food, travel and fees) from 19 companies. The largest payer was Amgen Inc. with $268.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 9 | $268 |
| Madrigal Pharmaceuticals MDGL | 10 | $255 |
| Novo Nordisk Inc NVO | 12 | $229 |
| Radius Health, Inc. | 6 | $167 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $152 |
| Sanofi-Aventis U.S. LLC SNY | 4 | $96.04 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $84.22 |
| Dexcom, Inc. DXCM | 3 | $79.35 |
| Lilly USA, LLC LLY | 3 | $62.65 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $57.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.